Phase 2 N=39 Randomized Triple-blind Treatment

Intraoperative Nitrous Oxide and Postoperative Pain for Patients With Current Opioid Treatment

Chronic Pain

Bottom Line

View on ClinicalTrials.gov: NCT00210158 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2025

Primary outcome: Primary: Post-operative Morphine Consumption — 54.6; 44.8 mg — p=0.5

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Air (Procedure); Protox (Procedure)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Institut Bergonié
Primary completion: Dec 2006

Outcome Measures

Outcome	Result	p-value
PRIMARY Post-operative Morphine Consumption	54.6; 44.8	0.5
SECONDARY Proportion of Participants With Post-operative Pain	2; 1	—

Summary

Peroperative opioids are known to induce N-Methyl-D-Aspartate dependent enhancement of postoperative hyperalgesia. For patients with current opioid treatment, these phenomena could be exagerated and could produce greater postoperative opioid consumption and higher pain score. Since Nitrous oxide has anti- N-Methyl-D-Aspartate properties, the aim of this study was to evaluate, in patients with current opioid treatment, the effects of peroperative Nitous oxide on postoperative opioid consumption and pain score, after vertebroplasty.

Eligibility Criteria

Older than 18 years
Current opioid treatment > 1 month
patients scheduled to undergo vertebroplasty with general anesthesia

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00210158). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.